These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 9314562

  • 1. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA.
    J Exp Med; 1997 Oct 06; 186(7):1137-47. PubMed ID: 9314562
    [Abstract] [Full Text] [Related]

  • 2. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
    Méndez S, Gurunathan S, Kamhawi S, Belkaid Y, Moga MA, Skeiky YA, Campos-Neto A, Reed S, Seder RA, Sacks D.
    J Immunol; 2001 Apr 15; 166(8):5122-8. PubMed ID: 11290794
    [Abstract] [Full Text] [Related]

  • 3. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S, Soto M, Carrión J, Alonso C, Requena JM.
    Vaccine; 2004 Sep 28; 22(29-30):3865-76. PubMed ID: 15364433
    [Abstract] [Full Text] [Related]

  • 4. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells.
    Gurunathan S, Stobie L, Prussin C, Sacks DL, Glaichenhaus N, Iwasaki A, Fowell DJ, Locksley RM, Chang JT, Wu CY, Seder RA.
    J Immunol; 2000 Jul 15; 165(2):915-24. PubMed ID: 10878366
    [Abstract] [Full Text] [Related]

  • 5. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
    Yamakami K, Akao S, Sato M, Nitta Y, Miyazaki J, Tadakuma T.
    Parasitol Int; 2001 Jul 15; 50(2):81-91. PubMed ID: 11438430
    [Abstract] [Full Text] [Related]

  • 6. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK.
    Tapia E, Pérez-Jiménez E, López-Fuertes L, Gonzalo R, Gherardi MM, Esteban M.
    Microbes Infect; 2003 Feb 15; 5(2):73-84. PubMed ID: 12650765
    [Abstract] [Full Text] [Related]

  • 7. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
    Coelho EA, Tavares CA, Carvalho FA, Chaves KF, Teixeira KN, Rodrigues RC, Charest H, Matlashewski G, Gazzinelli RT, Fernandes AP.
    Infect Immun; 2003 Jul 15; 71(7):3988-94. PubMed ID: 12819086
    [Abstract] [Full Text] [Related]

  • 8. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.
    Pérez-Jiménez E, Kochan G, Gherardi MM, Esteban M.
    Microbes Infect; 2006 Mar 15; 8(3):810-22. PubMed ID: 16504562
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection.
    Gurunathan S, Prussin C, Sacks DL, Seder RA.
    Nat Med; 1998 Dec 15; 4(12):1409-15. PubMed ID: 9846579
    [Abstract] [Full Text] [Related]

  • 11. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
    Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, Reed SG.
    Infect Immun; 2002 Jun 15; 70(6):2828-36. PubMed ID: 12010969
    [Abstract] [Full Text] [Related]

  • 12. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection.
    Stober CB, Lange UG, Roberts MT, Alcami A, Blackwell JM.
    J Immunol; 2005 Aug 15; 175(4):2517-24. PubMed ID: 16081824
    [Abstract] [Full Text] [Related]

  • 13. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice.
    López-Fuertes L, Pérez-Jiménez E, Vila-Coro AJ, Sack F, Moreno S, Konig SA, Junghans C, Wittig B, Timón M, Esteban M.
    Vaccine; 2002 Dec 13; 21(3-4):247-57. PubMed ID: 12450700
    [Abstract] [Full Text] [Related]

  • 14. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F, Di Roberto RB, Gillard J, Cousineau B.
    Vaccine; 2012 Aug 24; 30(39):5726-32. PubMed ID: 22814408
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S.
    Exp Parasitol; 2011 Mar 24; 127(3):627-36. PubMed ID: 21187087
    [Abstract] [Full Text] [Related]

  • 16. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S, Smith DF, Kaye PM.
    J Immunol; 2000 Dec 15; 165(12):7064-71. PubMed ID: 11120835
    [Abstract] [Full Text] [Related]

  • 17. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
    Pinto EF, Pinheiro RO, Rayol A, Larraga V, Rossi-Bergmann B.
    Infect Immun; 2004 Aug 15; 72(8):4521-7. PubMed ID: 15271911
    [Abstract] [Full Text] [Related]

  • 18. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge.
    Stobie L, Gurunathan S, Prussin C, Sacks DL, Glaichenhaus N, Wu CY, Seder RA.
    Proc Natl Acad Sci U S A; 2000 Jul 18; 97(15):8427-32. PubMed ID: 10890924
    [Abstract] [Full Text] [Related]

  • 19. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36.
    Gonzalo RM, Rodríguez JR, Rodríguez D, González-Aseguinolaza G, Larraga V, Esteban M.
    Microbes Infect; 2001 Jul 18; 3(9):701-11. PubMed ID: 11489418
    [Abstract] [Full Text] [Related]

  • 20. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge.
    Marques-da-Silva EA, Coelho EA, Gomes DC, Vilela MC, Masioli CZ, Tavares CA, Fernandes AP, Afonso LC, Rezende SA.
    Parasitol Res; 2005 Dec 18; 98(1):67-74. PubMed ID: 16261353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.